Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 25Lymphoma 21Neutropenia 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Non-Hodgkin 11Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Carcinoma, Non-Small-Cell Lung 8Multiple Myeloma 7Leukemia 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Urinary Bladder Neoplasms 4Testicular Neoplasms 4Sarcoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Hodgkin Disease 4Central Nervous System Neoplasms 4Testicular Germ Cell Tumor 3Teratoma 3Rhabdomyosarcoma 3Chemotherapy-induced Neutropenia 3Carcinoma, Ovarian Epithelial 3Carcinoma, Embryonal 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Cisplatin 68Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11camrelizumab 10Nivolumab 10Gemcitabine 10Drug Therapy 9tislelizumab 8Topotecan 8Taxes 8Chemoradiotherapy 8Radiation 7Docetaxel 7Albumin-Bound Paclitaxel 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × pegfilgrastim × Clear all
NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
27 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡